-
Nu.Q® Technology
Our technology detects characteristic epigenetic changes in nucleosomes that occur from the earliest stages of cancer, sepsis and other diseases.
-
- Our Tests
- Human Health
-
Nu.Q® NETs
Nu.Q® NETs is a groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis.
-
Nu.Q® Discover
Buy our Nu.Q® Discover H3.1 Research Use Only Assay
- Animal Health
-
Nu.Q® Vet Cancer Test
Nu.Q® Vet Cancer Test detects 76% of systemic cancers at 97% specificity.
![NETosis thumbnail](https://volition.com/wp-content/uploads/2024/07/NETosis-thumbnail.png)
![thumb](https://volition.com/wp-content/uploads/2024/07/thumb.jpg)
Dr Jake Micallef, Volition’s Chief Scientific Officer explains what NETosis is. He also outlines how Volition’s Nu.Q® NETs can be used to aid the detection and evaluation of diseases associated with NETosis.
Subscribe for Volition product updates.
Or, click here for Investor Updates and press releases.
"*" indicates required fields